BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Degoey DA, Chen H, Cox PB, Wendt MD. Beyond the Rule of 5: Lessons Learned from AbbVie’s Drugs and Compound Collection: Miniperspective. J Med Chem 2018;61:2636-51. [DOI: 10.1021/acs.jmedchem.7b00717] [Cited by in Crossref: 127] [Cited by in F6Publishing: 110] [Article Influence: 25.4] [Reference Citation Analysis]
Number Citing Articles
1 Pathania S, Singh PK. Analyzing FDA-approved drugs for compliance of pharmacokinetic principles: should there be a critical screening parameter in drug designing protocols? Expert Opin Drug Metab Toxicol 2021;17:351-4. [PMID: 33320017 DOI: 10.1080/17425255.2021.1865309] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Pettersson M, Crews CM. PROteolysis TArgeting Chimeras (PROTACs) - Past, present and future. Drug Discov Today Technol 2019;31:15-27. [PMID: 31200855 DOI: 10.1016/j.ddtec.2019.01.002] [Cited by in Crossref: 192] [Cited by in F6Publishing: 174] [Article Influence: 64.0] [Reference Citation Analysis]
3 Capecchi A, Awale M, Probst D, Reymond JL. PubChem and ChEMBL beyond Lipinski. Mol Inform 2019;38:e1900016. [PMID: 30844149 DOI: 10.1002/minf.201900016] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
4 Vekariya RH, Lei W, Ray A, Saini SK, Zhang S, Molnar G, Barlow D, Karlage KL, Bilsky EJ, Houseknecht KL, Largent-milnes TM, Streicher JM, Ananthan S. Synthesis and Structure–Activity Relationships of 5′-Aryl-14-alkoxypyridomorphinans: Identification of a μ Opioid Receptor Agonist/δ Opioid Receptor Antagonist Ligand with Systemic Antinociceptive Activity and Diminished Opioid Side Effects. J Med Chem 2020;63:7663-94. [DOI: 10.1021/acs.jmedchem.0c00503] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Caron G, Digiesi V, Solaro S, Ermondi G. Flexibility in early drug discovery: focus on the beyond-Rule-of-5 chemical space. Drug Discov Today 2020;25:621-7. [PMID: 31991117 DOI: 10.1016/j.drudis.2020.01.012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
6 Grygorenko OO, Volochnyuk DM, Ryabukhin SV, Judd DB. The Symbiotic Relationship Between Drug Discovery and Organic Chemistry. Chemistry 2020;26:1196-237. [PMID: 31429510 DOI: 10.1002/chem.201903232] [Cited by in Crossref: 43] [Cited by in F6Publishing: 19] [Article Influence: 14.3] [Reference Citation Analysis]
7 Sakai-Kato K, Yoshida K. The elution behavior of cyclosporine congeners in a developed HPLC system reflects the lipophilicity. J Pharm Biomed Anal 2020;180:113064. [PMID: 31896521 DOI: 10.1016/j.jpba.2019.113064] [Reference Citation Analysis]
8 Poongavanam V, Danelius E, Peintner S, Alcaraz L, Caron G, Cummings MD, Wlodek S, Erdelyi M, Hawkins PCD, Ermondi G, Kihlberg J. Conformational Sampling of Macrocyclic Drugs in Different Environments: Can We Find the Relevant Conformations? ACS Omega 2018;3:11742-57. [PMID: 30320271 DOI: 10.1021/acsomega.8b01379] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 12.0] [Reference Citation Analysis]
9 Scott KA, Cox PB, Njardarson JT. Phenols in Pharmaceuticals: Analysis of a Recurring Motif. J Med Chem 2022. [PMID: 35533692 DOI: 10.1021/acs.jmedchem.2c00223] [Reference Citation Analysis]
10 Rossi Sebastiano M, Doak BC, Backlund M, Poongavanam V, Over B, Ermondi G, Caron G, Matsson P, Kihlberg J. Impact of Dynamically Exposed Polarity on Permeability and Solubility of Chameleonic Drugs Beyond the Rule of 5. J Med Chem 2018;61:4189-202. [PMID: 29608068 DOI: 10.1021/acs.jmedchem.8b00347] [Cited by in Crossref: 79] [Cited by in F6Publishing: 66] [Article Influence: 19.8] [Reference Citation Analysis]
11 Du J, Liu L, Liu B, Yang J, Hou X, Yu J, Fang H. Structure-based virtual screening, biological evaluation and biophysical study of novel Mcl-1 inhibitors. Future Med Chem 2020;12:1293-304. [PMID: 32397829 DOI: 10.4155/fmc-2020-0114] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
12 Harvey EP, Hauseman ZJ, Cohen DT, Rettenmaier TJ, Lee S, Huhn AJ, Wales TE, Seo HS, Luccarelli J, Newman CE, Guerra RM, Bird GH, Dhe-Paganon S, Engen JR, Wells JA, Walensky LD. Identification of a Covalent Molecular Inhibitor of Anti-apoptotic BFL-1 by Disulfide Tethering. Cell Chem Biol 2020;27:647-656.e6. [PMID: 32413285 DOI: 10.1016/j.chembiol.2020.04.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
13 Yang C, Qin C, Bai L, Wang S. Small-molecule PROTAC degraders of the Bromodomain and Extra Terminal (BET) proteins — A review. Drug Discovery Today: Technologies 2019;31:43-51. [DOI: 10.1016/j.ddtec.2019.04.001] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 13.3] [Reference Citation Analysis]
14 Bojadzic D, Chen J, Alcazar O, Buchwald P. Design, Synthesis, and Evaluation of Novel Immunomodulatory Small Molecules Targeting the CD40⁻CD154 Costimulatory Protein-Protein Interaction. Molecules 2018;23:E1153. [PMID: 29751636 DOI: 10.3390/molecules23051153] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
15 Chandra Manivannan A, Malaisamy A, Eswaran M, Meyyazhagan A, Arumugam VA, Rengasamy KRR, Balasubramanian B, Liu W. Evaluation of Clove Phytochemicals as Potential Antiviral Drug Candidates Targeting SARS-CoV-2 Main Protease: Computational Docking, Molecular Dynamics Simulation, and Pharmacokinetic Profiling. Front Mol Biosci 2022;9:918101. [DOI: 10.3389/fmolb.2022.918101] [Reference Citation Analysis]
16 Castan IFSF, Graham JS, Salvini CLA, Stanway-Gordon HA, Waring MJ. On the design of lead-like DNA-encoded chemical libraries. Bioorg Med Chem 2021;43:116273. [PMID: 34147943 DOI: 10.1016/j.bmc.2021.116273] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Khan MT, Ali A, Wang Q, Irfan M, Khan A, Zeb MT, Zhang YJ, Chinnasamy S, Wei DQ. Marine natural compounds as potents inhibitors against the main protease of SARS-CoV-2-a molecular dynamic study. J Biomol Struct Dyn 2021;39:3627-37. [PMID: 32410504 DOI: 10.1080/07391102.2020.1769733] [Cited by in Crossref: 27] [Cited by in F6Publishing: 38] [Article Influence: 13.5] [Reference Citation Analysis]
18 Foloppe N, Chen IJ. The reorganization energy of compounds upon binding to proteins, from dynamic and solvated bound and unbound states. Bioorg Med Chem 2021;51:116464. [PMID: 34798378 DOI: 10.1016/j.bmc.2021.116464] [Reference Citation Analysis]
19 Egbert M, Whitty A, Keserű GM, Vajda S. Why Some Targets Benefit from beyond Rule of Five Drugs. J Med Chem 2019;62:10005-25. [PMID: 31188592 DOI: 10.1021/acs.jmedchem.8b01732] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 10.0] [Reference Citation Analysis]
20 Voight EA, Greszler SN, Hartung J, Ji J, Klix RC, Randolph JT, Shelat BH, Waters JE, DeGoey DA. Desymmetrization of pibrentasvir for efficient prodrug synthesis. Chem Sci 2021;12:10076-82. [PMID: 34349971 DOI: 10.1039/d1sc02396a] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Radchenko DS, Naumchyk VS, Dziuba I, Kyrylchuk AA, Gubina KE, Moroz YS, Grygorenko OO. One-pot parallel synthesis of 1,3,5-trisubstituted 1,2,4-triazoles. Mol Divers 2021. [PMID: 33797670 DOI: 10.1007/s11030-021-10218-2] [Reference Citation Analysis]
22 Bojadzic D, Alcazar O, Chen J, Chuang ST, Condor Capcha JM, Shehadeh LA, Buchwald P. Small-Molecule Inhibitors of the Coronavirus Spike: ACE2 Protein-Protein Interaction as Blockers of Viral Attachment and Entry for SARS-CoV-2. ACS Infect Dis 2021;7:1519-34. [PMID: 33979123 DOI: 10.1021/acsinfecdis.1c00070] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 20.0] [Reference Citation Analysis]
23 Atilaw Y, Poongavanam V, Svensson Nilsson C, Nguyen D, Giese A, Meibom D, Erdelyi M, Kihlberg J. Solution Conformations Shed Light on PROTAC Cell Permeability. ACS Med Chem Lett 2021;12:107-14. [PMID: 33488971 DOI: 10.1021/acsmedchemlett.0c00556] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 25.0] [Reference Citation Analysis]
24 Vinarov Z, Abrahamsson B, Artursson P, Batchelor H, Berben P, Bernkop-Schnürch A, Butler J, Ceulemans J, Davies N, Dupont D, Flaten GE, Fotaki N, Griffin BT, Jannin V, Keemink J, Kesisoglou F, Koziolek M, Kuentz M, Mackie A, Meléndez-Martínez AJ, McAllister M, Müllertz A, O'Driscoll CM, Parrott N, Paszkowska J, Pavek P, Porter CJH, Reppas C, Stillhart C, Sugano K, Toader E, Valentová K, Vertzoni M, De Wildt SN, Wilson CG, Augustijns P. Current challenges and future perspectives in oral absorption research: An opinion of the UNGAP network. Adv Drug Deliv Rev 2021;171:289-331. [PMID: 33610694 DOI: 10.1016/j.addr.2021.02.001] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 30.0] [Reference Citation Analysis]
25 Hong RS, Mattei A, Sheikh AY, Bhardwaj RM, Bellucci MA, McDaniel KF, Pierce MO, Sun G, Li S, Wang L, Mondal S, Ji J, Borchardt TB. Novel Physics-Based Ensemble Modeling Approach That Utilizes 3D Molecular Conformation and Packing to Access Aqueous Thermodynamic Solubility: A Case Study of Orally Available Bromodomain and Extraterminal Domain Inhibitor Lead Optimization Series. J Chem Inf Model 2021;61:1412-26. [PMID: 33661005 DOI: 10.1021/acs.jcim.0c01410] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
26 Tyagi M, Begnini F, Poongavanam V, Doak BC, Kihlberg J. Drug Syntheses Beyond the Rule of 5. Chem Eur J 2020;26:49-88. [DOI: 10.1002/chem.201902716] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
27 Meanwell NA, Georg GI, Wang S. The 2020 Nobel Prize in Physiology or Medicine. J Med Chem 2020;63:13197-204. [PMID: 33147952 DOI: 10.1021/acs.jmedchem.0c01877] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
28 Poongavanam V, Doak BC, Kihlberg J. Opportunities and guidelines for discovery of orally absorbed drugs in beyond rule of 5 space. Current Opinion in Chemical Biology 2018;44:23-9. [DOI: 10.1016/j.cbpa.2018.05.010] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
29 Leissing TM, Luh LM, Cromm PM. Structure driven compound optimization in targeted protein degradation. Drug Discovery Today: Technologies 2020. [DOI: 10.1016/j.ddtec.2020.11.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
30 Begnini F, Poongavanam V, Over B, Castaldo M, Geschwindner S, Johansson P, Tyagi M, Tyrchan C, Wissler L, Sjö P, Schiesser S, Kihlberg J. Mining Natural Products for Macrocycles to Drug Difficult Targets. J Med Chem 2021;64:1054-72. [PMID: 33337880 DOI: 10.1021/acs.jmedchem.0c01569] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
31 Voight EA, Greszler SN, Kym PR. Fueling the Pipeline via Innovations in Organic Synthesis. ACS Med Chem Lett 2021;12:1365-73. [PMID: 34531945 DOI: 10.1021/acsmedchemlett.1c00351] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Shultz MD. Two Decades under the Influence of the Rule of Five and the Changing Properties of Approved Oral Drugs: Miniperspective. J Med Chem 2019;62:1701-14. [DOI: 10.1021/acs.jmedchem.8b00686] [Cited by in Crossref: 132] [Cited by in F6Publishing: 112] [Article Influence: 33.0] [Reference Citation Analysis]
33 Meanwell NA. Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design. J Med Chem 2018;61:5822-80. [PMID: 29400967 DOI: 10.1021/acs.jmedchem.7b01788] [Cited by in Crossref: 630] [Cited by in F6Publishing: 432] [Article Influence: 157.5] [Reference Citation Analysis]
34 Green AI, Burslem GM. Focused Libraries for Epigenetic Drug Discovery: The Importance of Isosteres. J Med Chem 2021;64:7231-40. [PMID: 34042449 DOI: 10.1021/acs.jmedchem.1c00592] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
35 Troup RI, Fallan C, Baud MGJ. Current strategies for the design of PROTAC linkers: a critical review. Exploration of Targeted Anti-tumor Therapy 2020;1. [DOI: 10.37349/etat.2020.00018] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
36 Hill J, Crich D. The N,N,O-Trisubstituted Hydroxylamine Isostere and Its Influence on Lipophilicity and Related Parameters. ACS Med Chem Lett 2022;13:799-806. [PMID: 35586423 DOI: 10.1021/acsmedchemlett.1c00713] [Reference Citation Analysis]
37 Pathak N, Fatima K, Singh S, Mishra D, Gupta AC, Kumar Y, Chanda D, Bawankule D, Shanker K, Khan F, Gupta A, Luqman S, Negi AS. Bivalent furostene carbamates as antiproliferative and antiinflammatory agents. The Journal of Steroid Biochemistry and Molecular Biology 2019;194:105457. [DOI: 10.1016/j.jsbmb.2019.105457] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
38 Bhanot A, Sundriyal S. Physicochemical Profiling and Comparison of Research Antiplasmodials and Advanced Stage Antimalarials with Oral Drugs. ACS Omega 2021;6:6424-37. [PMID: 33718733 DOI: 10.1021/acsomega.1c00104] [Reference Citation Analysis]
39 Yang Z, He J, Lu A, Hou T, Cao D. Application of Negative Design To Design a More Desirable Virtual Screening Library. J Med Chem 2020;63:4411-29. [DOI: 10.1021/acs.jmedchem.9b01476] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
40 Prerna K, Dubey VK. Repurposing of FDA-approved drugs as autophagy inhibitors in tumor cells. J Biomol Struct Dyn 2021;:1-12. [PMID: 33467992 DOI: 10.1080/07391102.2021.1873862] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Newman DJ, Cragg GM. Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019. J Nat Prod. 2020;83:770-803. [PMID: 32162523 DOI: 10.1021/acs.jnatprod.9b01285] [Cited by in Crossref: 622] [Cited by in F6Publishing: 560] [Article Influence: 311.0] [Reference Citation Analysis]
42 Ermondi G, Vallaro M, Goetz G, Shalaeva M, Caron G. Experimental lipophilicity for beyond Rule of 5 compounds. Future Drug Discovery 2019;1:FDD10. [DOI: 10.4155/fdd-2019-0002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
43 Dahlin JL, Auld DS, Rothenaigner I, Haney S, Sexton JZ, Nissink JWM, Walsh J, Lee JA, Strelow JM, Willard FS, Ferrins L, Baell JB, Walters MA, Hua BK, Hadian K, Wagner BK. Nuisance compounds in cellular assays. Cell Chem Biol 2021;28:356-70. [PMID: 33592188 DOI: 10.1016/j.chembiol.2021.01.021] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
44 Tinworth CP, Young RJ. Facts, Patterns, and Principles in Drug Discovery: Appraising the Rule of 5 with Measured Physicochemical Data. J Med Chem 2020;63:10091-108. [PMID: 32324397 DOI: 10.1021/acs.jmedchem.9b01596] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 7.5] [Reference Citation Analysis]
45 Di L, Artursson P, Avdeef A, Benet LZ, Houston JB, Kansy M, Kerns EH, Lennernäs H, Smith DA, Sugano K. The Critical Role of Passive Permeability in Designing Successful Drugs. ChemMedChem 2020;15:1862-74. [PMID: 32743945 DOI: 10.1002/cmdc.202000419] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
46 Aicher TD, Van Huis CA, Hurd AR, Skalitzky DJ, Taylor CB, Beleh OM, Glick G, Toogood PL, Yang B, Zheng T, Huo C, Gao J, Qiao C, Tian X, Zhang J, Demock K, Hao LY, Lesch CA, Morgan RW, Moisan J, Wang Y, Scatina J, Paulos CM, Zou W, Carter LL, Hu X. Discovery of LYC-55716: A Potent, Selective, and Orally Bioavailable Retinoic Acid Receptor-Related Orphan Receptor-γ (RORγ) Agonist for Use in Treating Cancer. J Med Chem 2021;64:13410-28. [PMID: 34499493 DOI: 10.1021/acs.jmedchem.1c00731] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Xiang W, Zhao L, Han X, Qin C, Miao B, McEachern D, Wang Y, Metwally H, Kirchhoff PD, Wang L, Matvekas A, He M, Wen B, Sun D, Wang S. Discovery of ARD-2585 as an Exceptionally Potent and Orally Active PROTAC Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer. J Med Chem 2021;64:13487-509. [PMID: 34473519 DOI: 10.1021/acs.jmedchem.1c00900] [Reference Citation Analysis]
48 Tomoshige S, Ishikawa M. In vivo synthetic chemistry of proteolysis targeting chimeras (PROTACs). Bioorg Med Chem 2021;41:116221. [PMID: 34034148 DOI: 10.1016/j.bmc.2021.116221] [Reference Citation Analysis]
49 Caron G, Kihlberg J, Ermondi G. Intramolecular hydrogen bonding: An opportunity for improved design in medicinal chemistry. Med Res Rev 2019;39:1707-29. [PMID: 30659634 DOI: 10.1002/med.21562] [Cited by in Crossref: 34] [Cited by in F6Publishing: 24] [Article Influence: 11.3] [Reference Citation Analysis]
50 Gala UH, Miller DA, Williams RO 3rd. Harnessing the therapeutic potential of anticancer drugs through amorphous solid dispersions. Biochim Biophys Acta Rev Cancer 2020;1873:188319. [PMID: 31678141 DOI: 10.1016/j.bbcan.2019.188319] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
51 Magotra A, Gour A, Sharma DK, Dash AK, Singh G, Mukherjee D, Nandi U. Pharmacokinetic evaluation of medicinally important synthetic N,N' diindolylmethane glucoside: Improved synthesis and metabolic stability. Bioorg Med Chem Lett 2019;29:1007-11. [PMID: 30777609 DOI: 10.1016/j.bmcl.2019.02.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
52 Watanabe A, Uehara S, Akazawa T, Fujiu M. Optimization of cyclic peptide property using chromatographic capacity factor on permeability of passive cell membrane and human induced pluripotent stem cell-derived intestinal membrane. Journal of Pharmaceutical Sciences 2022. [DOI: 10.1016/j.xphs.2022.03.019] [Reference Citation Analysis]
53 Bojadzic D, Buchwald P. Toward Small-Molecule Inhibition of Protein-Protein Interactions: General Aspects and Recent Progress in Targeting Costimulatory and Coinhibitory (Immune Checkpoint) Interactions. Curr Top Med Chem 2018;18:674-99. [PMID: 29848279 DOI: 10.2174/1568026618666180531092503] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 8.3] [Reference Citation Analysis]
54 Norman BH. Drug Induced Liver Injury (DILI). Mechanisms and Medicinal Chemistry Avoidance/Mitigation Strategies. J Med Chem 2020;63:11397-419. [PMID: 32511920 DOI: 10.1021/acs.jmedchem.0c00524] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
55 Edmondson SD, Yang B, Fallan C. Proteolysis targeting chimeras (PROTACs) in ‘beyond rule-of-five’ chemical space: Recent progress and future challenges. Bioorganic & Medicinal Chemistry Letters 2019;29:1555-64. [DOI: 10.1016/j.bmcl.2019.04.030] [Cited by in Crossref: 91] [Cited by in F6Publishing: 80] [Article Influence: 30.3] [Reference Citation Analysis]
56 Cantrill C, Chaturvedi P, Rynn C, Petrig Schaffland J, Walter I, Wittwer MB. Fundamental aspects of DMPK optimization of targeted protein degraders. Drug Discov Today 2020;25:969-82. [PMID: 32298797 DOI: 10.1016/j.drudis.2020.03.012] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 12.0] [Reference Citation Analysis]
57 Albertini C, Naldi M, Petralla S, Strocchi S, Grifoni D, Monti B, Bartolini M, Bolognesi ML. From Combinations to Single-Molecule Polypharmacology-Cromolyn-Ibuprofen Conjugates for Alzheimer's Disease. Molecules 2021;26:1112. [PMID: 33669839 DOI: 10.3390/molecules26041112] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
58 Pande M, Kundu D, Srivastava R. Drugs repurposing against SARS-CoV2 and the new variant B.1.1.7 (alpha strain) targeting the spike protein: molecular docking and simulation studies. Heliyon 2021;7:e07803. [PMID: 34423145 DOI: 10.1016/j.heliyon.2021.e07803] [Reference Citation Analysis]
59 Sheikh AY, Mattei A, Miglani Bhardwaj R, Hong RS, Abraham NS, Schneider-Rauber G, Engstrom KM, Diwan M, Henry RF, Gao Y, Juarez V, Jordan E, DeGoey DA, Hutchins CW. Implications of the Conformationally Flexible, Macrocyclic Structure of the First-Generation, Direct-Acting Anti-Viral Paritaprevir on Its Solid Form Complexity and Chameleonic Behavior. J Am Chem Soc 2021;143:17479-91. [PMID: 34637297 DOI: 10.1021/jacs.1c06837] [Reference Citation Analysis]
60 Fullam E, Young RJ. Physicochemical properties and Mycobacterium tuberculosis transporters: keys to efficacious antitubercular drugs? RSC Med Chem 2020;12:43-56. [PMID: 34041481 DOI: 10.1039/d0md00265h] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
61 Srivastava A, Pike A, Williamson B, Fenner K. A Novel Method for Preventing Non-specific Binding in Equilibrium Dialysis Assays Using Solutol® as an Additive. J Pharm Sci 2021;110:1412-7. [PMID: 33248055 DOI: 10.1016/j.xphs.2020.11.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
62 Hughes SJ, Testa A, Thompson N, Churcher I. The rise and rise of protein degradation: Opportunities and challenges ahead. Drug Discov Today 2021;26:2889-97. [PMID: 34419629 DOI: 10.1016/j.drudis.2021.08.006] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
63 Leeson PD, Bento AP, Gaulton A, Hersey A, Manners EJ, Radoux CJ, Leach AR. Target-Based Evaluation of "Drug-Like" Properties and Ligand Efficiencies. J Med Chem 2021;64:7210-30. [PMID: 33983732 DOI: 10.1021/acs.jmedchem.1c00416] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
64 Chang CK, Lin SM, Satange R, Lin SC, Sun SC, Wu HY, Kehn-Hall K, Hou MH. Targeting protein-protein interaction interfaces in COVID-19 drug discovery. Comput Struct Biotechnol J 2021;19:2246-55. [PMID: 33936565 DOI: 10.1016/j.csbj.2021.04.003] [Reference Citation Analysis]
65 Brown BP, Vu O, Geanes AR, Kothiwale S, Butkiewicz M, Lowe EW, Mueller R, Pape R, Mendenhall J, Meiler J. Introduction to the BioChemical Library (BCL): An Application-Based Open-Source Toolkit for Integrated Cheminformatics and Machine Learning in Computer-Aided Drug Discovery. Front Pharmacol 2022;13:833099. [DOI: 10.3389/fphar.2022.833099] [Reference Citation Analysis]
66 Mahmoud SY, Svensson F, Zoufir A, Módos D, Afzal AM, Bender A. Understanding Conditional Associations between ToxCast in Vitro Readouts and the Hepatotoxicity of Compounds Using Rule-Based Methods. Chem Res Toxicol 2020;33:137-53. [DOI: 10.1021/acs.chemrestox.8b00382] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
67 Riching KM, Vasta JD, Hughes SJ, Zoppi V, Maniaci C, Testa A, Urh M, Ciulli A, Daniels DL. Translating PROTAC chemical series optimization into functional outcomes underlying BRD7 and BRD9 protein degradation. Current Research in Chemical Biology 2021;1:100009. [DOI: 10.1016/j.crchbi.2021.100009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
68 Young RJ, Leeson PD. Mapping the Efficiency and Physicochemical Trajectories of Successful Optimizations. J Med Chem 2018;61:6421-67. [DOI: 10.1021/acs.jmedchem.8b00180] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 10.0] [Reference Citation Analysis]
69 O'Shea JP, Augustijns P, Brandl M, Brayden DJ, Brouwers J, Griffin BT, Holm R, Jacobsen AC, Lennernäs H, Vinarov Z, O'Driscoll CM. Best practices in current models mimicking drug permeability in the gastrointestinal tract - an UNGAP review. Eur J Pharm Sci 2021;:106098. [PMID: 34954051 DOI: 10.1016/j.ejps.2021.106098] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
70 Randolph JT, Voight EA, Greszler SN, Uno BE, Newton JN, Gleason KM, Stolarik D, Van Handel C, Bow DAJ, DeGoey DA. Prodrug Strategies to Improve the Solubility of the HCV NS5A Inhibitor Pibrentasvir (ABT-530). J Med Chem 2020;63:11034-44. [PMID: 32881503 DOI: 10.1021/acs.jmedchem.0c00956] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
71 Brown DG, Wobst HJ. A Decade of FDA-Approved Drugs (2010-2019): Trends and Future Directions. J Med Chem 2021;64:2312-38. [PMID: 33617254 DOI: 10.1021/acs.jmedchem.0c01516] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
72 Brown DG, Smith GF, Wobst HJ. Promiscuity of in Vitro Secondary Pharmacology Assays and Implications for Lead Optimization Strategies. J Med Chem 2020;63:6251-75. [PMID: 31714773 DOI: 10.1021/acs.jmedchem.9b01625] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
73 Rehman AU, Lu S, Khan AA, Khurshid B, Rasheed S, Wadood A, Zhang J. Hidden allosteric sites and De-Novo drug design. Expert Opin Drug Discov 2021;:1-13. [PMID: 34933653 DOI: 10.1080/17460441.2022.2017876] [Reference Citation Analysis]
74 Lazzara PR, David BP, Ankireddy A, Richardson BG, Dye K, Ratia KM, Reddy SP, Moore TW. Isoquinoline Kelch-like ECH-Associated Protein 1-Nuclear Factor (Erythroid-Derived 2)-like 2 (KEAP1-NRF2) Inhibitors with High Metabolic Stability. J Med Chem 2020;63:6547-60. [PMID: 31682434 DOI: 10.1021/acs.jmedchem.9b01074] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
75 Mukherjee S, Sharma D, Sharma AK, Jaiswal S, Sharma N, Borah S, Kaur G. Flavan-based phytoconstituents inhibit Mpro, a SARS-COV-2 molecular target, in silico. J Biomol Struct Dyn 2021;:1-15. [PMID: 34348081 DOI: 10.1080/07391102.2021.1960196] [Reference Citation Analysis]
76 Liras S, Mcclure KF. Permeability of Cyclic Peptide Macrocycles and Cyclotides and Their Potential as Therapeutics. ACS Med Chem Lett 2019;10:1026-32. [PMID: 31312403 DOI: 10.1021/acsmedchemlett.9b00149] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
77 Ermondi G, Vallaro M, Goetz G, Shalaeva M, Caron G. Updating the portfolio of physicochemical descriptors related to permeability in the beyond the rule of 5 chemical space. Eur J Pharm Sci 2020;146:105274. [PMID: 32088315 DOI: 10.1016/j.ejps.2020.105274] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
78 Miglani Bhardwaj R, Ho R, Gui Y, Brackemeyer P, Schneider-rauber G, Nordstrom FL, Sheikh AY. Origins and Implications of Extraordinarily Soft Crystals in a Fixed-Dose Combination Hepatitis C Regimen. Crystal Growth & Design. [DOI: 10.1021/acs.cgd.2c00264] [Reference Citation Analysis]
79 Serafini M, Cargnin S, Massarotti A, Tron GC, Pirali T, Genazzani AA. What's in a Name? Drug Nomenclature and Medicinal Chemistry Trends using INN Publications. J Med Chem 2021;64:4410-29. [PMID: 33847110 DOI: 10.1021/acs.jmedchem.1c00181] [Reference Citation Analysis]
80 Koehl NJ, Henze LJ, Holm R, Kuentz M, Keating JJ, De Vijlder T, Marx A, Griffin BT. Lipophilic Salts and Lipid-Based Formulations for Bridging the Food Effect Gap of Venetoclax. J Pharm Sci 2021:S0022-3549(21)00475-5. [PMID: 34516990 DOI: 10.1016/j.xphs.2021.09.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
81 Jimenez DG, Sebastiano MR, Caron G, Ermondi G. Are we ready to design oral PROTACs®? ADMET DMPK 2021;9:243-54. [PMID: 35300370 DOI: 10.5599/admet.1037] [Reference Citation Analysis]
82 Yang W, Gadgil P, Krishnamurthy VR, Landis M, Mallick P, Patel D, Patel PJ, Reid DL, Sanchez-felix M. The Evolving Druggability and Developability Space: Chemically Modified New Modalities and Emerging Small Molecules. AAPS J 2020;22. [DOI: 10.1208/s12248-019-0402-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
83 Brayden DJ, Hill TA, Fairlie DP, Maher S, Mrsny RJ. Systemic delivery of peptides by the oral route: Formulation and medicinal chemistry approaches. Adv Drug Deliv Rev 2020;157:2-36. [PMID: 32479930 DOI: 10.1016/j.addr.2020.05.007] [Cited by in Crossref: 73] [Cited by in F6Publishing: 63] [Article Influence: 36.5] [Reference Citation Analysis]
84 Price E, Kalvass JC, DeGoey D, Hosmane B, Doktor S, Desino K. Global Analysis of Models for Predicting Human Absorption: QSAR, In Vitro, and Preclinical Models. J Med Chem 2021;64:9389-403. [PMID: 34152772 DOI: 10.1021/acs.jmedchem.1c00669] [Reference Citation Analysis]
85 Vajda S, Beglov D, Wakefield AE, Egbert M, Whitty A. Cryptic binding sites on proteins: definition, detection, and druggability. Curr Opin Chem Biol 2018;44:1-8. [PMID: 29800865 DOI: 10.1016/j.cbpa.2018.05.003] [Cited by in Crossref: 51] [Cited by in F6Publishing: 38] [Article Influence: 12.8] [Reference Citation Analysis]
86 Poongavanam V, Kihlberg J. PROTAC cell permeability and oral bioavailability: a journey into uncharted territory. Future Med Chem 2021. [PMID: 34583518 DOI: 10.4155/fmc-2021-0208] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
87 Corbett KM, Ford L, Warren DB, Pouton CW, Chalmers DK. Cyclosporin Structure and Permeability: From A to Z and Beyond. J Med Chem 2021;64:13131-51. [PMID: 34478303 DOI: 10.1021/acs.jmedchem.1c00580] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
88 Grygorenko OO, Radchenko DS, Dziuba I, Chuprina A, Gubina KE, Moroz YS. Generating Multibillion Chemical Space of Readily Accessible Screening Compounds. iScience 2020;23:101681. [DOI: 10.1016/j.isci.2020.101681] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
89 Wu G, Zhao T, Kang D, Zhang J, Song Y, Namasivayam V, Kongsted J, Pannecouque C, De Clercq E, Poongavanam V, Liu X, Zhan P. Overview of Recent Strategic Advances in Medicinal Chemistry. J Med Chem 2019;62:9375-414. [PMID: 31050421 DOI: 10.1021/acs.jmedchem.9b00359] [Cited by in Crossref: 44] [Cited by in F6Publishing: 36] [Article Influence: 14.7] [Reference Citation Analysis]
90 Avdeef A, Kansy M. "Flexible-Acceptor" General Solubility Equation for beyond Rule of 5 Drugs. Mol Pharm 2020;17:3930-40. [PMID: 32787270 DOI: 10.1021/acs.molpharmaceut.0c00689] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
91 Yu J, Noda H, Shibasaki M. Exploiting β-Amino Acid Enolates in Direct Catalytic Diastereo- and Enantioselective C−C Bond-Forming Reactions. Chem Eur J 2018;24:15796-800. [DOI: 10.1002/chem.201804346] [Cited by in Crossref: 24] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
92 Humbeck L, Weigang S, Schäfer T, Mutzel P, Koch O. CHIPMUNK: A Virtual Synthesizable Small-Molecule Library for Medicinal Chemistry, Exploitable for Protein-Protein Interaction Modulators. ChemMedChem 2018;13:532-9. [PMID: 29392860 DOI: 10.1002/cmdc.201700689] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
93 Koehl NJ, Henze LJ, Bennett-Lenane H, Faisal W, Price DJ, Holm R, Kuentz M, Griffin BT. In Silico, In Vitro, and In Vivo Evaluation of Precipitation Inhibitors in Supersaturated Lipid-Based Formulations of Venetoclax. Mol Pharm 2021;18:2174-88. [PMID: 33890794 DOI: 10.1021/acs.molpharmaceut.0c00645] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
94 Tyagi M, Poongavanam V, Lindhagen M, Pettersen A, Sjö P, Schiesser S, Kihlberg J. Toward the Design of Molecular Chameleons: Flexible Shielding of an Amide Bond Enhances Macrocycle Cell Permeability. Org Lett 2018;20:5737-42. [DOI: 10.1021/acs.orglett.8b02447] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
95 Lenci E, Trabocchi A. Synthetic approaches toward small molecule libraries. Small Molecule Drug Discovery. Elsevier; 2020. pp. 1-34. [DOI: 10.1016/b978-0-12-818349-6.00001-7] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
96 Wagner-Griffin S, Abe M, Benhamou RI, Angelbello AJ, Vishnu K, Chen JL, Childs-Disney JL, Disney MD. A Druglike Small Molecule that Targets r(CCUG) Repeats in Myotonic Dystrophy Type 2 Facilitates Degradation by RNA Quality Control Pathways. J Med Chem 2021;64:8474-85. [PMID: 34101465 DOI: 10.1021/acs.jmedchem.1c00414] [Reference Citation Analysis]
97 Guedes RA, Aniceto N, Andrade MAP, Salvador JAR, Guedes RC. Chemical Patterns of Proteasome Inhibitors: Lessons Learned from Two Decades of Drug Design. Int J Mol Sci 2019;20:E5326. [PMID: 31731563 DOI: 10.3390/ijms20215326] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
98 Shah RR, Redmond JM, Mihut A, Menon M, Evans JP, Murphy JA, Bartholomew MA, Coe DM. Hi-JAK-ing the ubiquitin system: The design and physicochemical optimisation of JAK PROTACs. Bioorg Med Chem 2020;28:115326. [PMID: 32001089 DOI: 10.1016/j.bmc.2020.115326] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
99 Viarengo-Baker LA, Brown LE, Rzepiela AA, Whitty A. Defining and navigating macrocycle chemical space. Chem Sci 2021;12:4309-28. [PMID: 34163695 DOI: 10.1039/d0sc05788f] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
100 Antoni F, Wifling D, Bernhardt G. Water-soluble inhibitors of ABCG2 (BCRP) - A fragment-based and computational approach. Eur J Med Chem 2021;210:112958. [PMID: 33199153 DOI: 10.1016/j.ejmech.2020.112958] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
101 Yang ZY, Yang ZJ, Lu AP, Hou TJ, Cao DS. Scopy: an integrated negative design python library for desirable HTS/VS database design. Brief Bioinform 2021;22:bbaa194. [PMID: 32892221 DOI: 10.1093/bib/bbaa194] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
102 Liu Y, Zhang L, Yan H, Wang Z, Sun G, Song X, Zhou Z, Peng B, Yan L, Wu Q, Li W, Qi X. Design of Dimeric Bile Acid Derivatives as Potent and Selective Human NTCP Inhibitors. J Med Chem 2021;64:5973-6007. [PMID: 33906348 DOI: 10.1021/acs.jmedchem.1c00078] [Reference Citation Analysis]
103 Ermondi G, Garcia-Jimenez D, Caron G. PROTACs and Building Blocks: The 2D Chemical Space in Very Early Drug Discovery. Molecules 2021;26:672. [PMID: 33525371 DOI: 10.3390/molecules26030672] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
104 Protti ÍF, Rodrigues DR, Fonseca SK, Alves RJ, de Oliveira RB, Maltarollo VG. Do Drug-likeness Rules Apply to Oral Prodrugs? ChemMedChem 2021;16:1446-56. [PMID: 33471444 DOI: 10.1002/cmdc.202000805] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
105 Szlávik Z, Ondi L, Csékei M, Paczal A, Szabó ZB, Radics G, Murray J, Davidson J, Chen I, Davis B, Hubbard RE, Pedder C, Dokurno P, Surgenor A, Smith J, Robertson A, Letoumelin-braizat G, Cauquil N, Zarka M, Demarles D, Perron-sierra F, Claperon A, Colland F, Geneste O, Kotschy A. Structure-Guided Discovery of a Selective Mcl-1 Inhibitor with Cellular Activity. J Med Chem 2019;62:6913-24. [DOI: 10.1021/acs.jmedchem.9b00134] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 8.0] [Reference Citation Analysis]
106 Wadanambi PM, Mannapperuma U. Computational study to discover potent phytochemical inhibitors against drug target, squalene synthase from Leishmania donovani. Heliyon 2021;7:e07178. [PMID: 34141935 DOI: 10.1016/j.heliyon.2021.e07178] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
107 Ivanenkov YA, Zagribelnyy BA, Aladinskiy VA. Are We Opening the Door to a New Era of Medicinal Chemistry or Being Collapsed to a Chemical Singularity? J Med Chem 2019;62:10026-43. [PMID: 31188596 DOI: 10.1021/acs.jmedchem.9b00004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
108 Ursu A, Vézina-Dawod S, Disney MD. Methods to identify and optimize small molecules interacting with RNA (SMIRNAs). Drug Discov Today 2019;24:2002-16. [PMID: 31356880 DOI: 10.1016/j.drudis.2019.06.019] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
109 Giustiniano M, Gruber CW, Kent CN, Trippier PC. Back to the Medicinal Chemistry Future. J Med Chem 2021;64:15515-8. [PMID: 34719927 DOI: 10.1021/acs.jmedchem.1c01788] [Reference Citation Analysis]
110 Dawidowski M, Kalel VC, Napolitano V, Fino R, Schorpp K, Emmanouilidis L, Lenhart D, Ostertag M, Kaiser M, Kolonko M, Tippler B, Schliebs W, Dubin G, Mäser P, Tetko IV, Hadian K, Plettenburg O, Erdmann R, Sattler M, Popowicz GM. Structure-Activity Relationship in Pyrazolo[4,3-c]pyridines, First Inhibitors of PEX14-PEX5 Protein-Protein Interaction with Trypanocidal Activity. J Med Chem 2020;63:847-79. [PMID: 31860309 DOI: 10.1021/acs.jmedchem.9b01876] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
111 Maryanoff BE, Wipf P. Medicinal Chemistry: From Targets to Therapies. ACS Med Chem Lett 2019;10:1014. [PMID: 31312399 DOI: 10.1021/acsmedchemlett.9b00244] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
112 Saldívar-González FI, Aldas-Bulos VD, Medina-Franco JL, Plisson F. Natural product drug discovery in the artificial intelligence era. Chem Sci 2022;13:1526-46. [PMID: 35282622 DOI: 10.1039/d1sc04471k] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
113 Slack RJ, Macdonald SJF, Roper JA, Jenkins RG, Hatley RJD. Emerging therapeutic opportunities for integrin inhibitors. Nat Rev Drug Discov 2021. [PMID: 34535788 DOI: 10.1038/s41573-021-00284-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
114 Wei W, Cherukupalli S, Jing L, Liu X, Zhan P. Fsp3: A new parameter for drug-likeness. Drug Discov Today 2020:S1359-6446(20)30297-X. [PMID: 32712310 DOI: 10.1016/j.drudis.2020.07.017] [Cited by in Crossref: 28] [Cited by in F6Publishing: 16] [Article Influence: 14.0] [Reference Citation Analysis]
115 Caron G, Kihlberg J, Goetz G, Ratkova E, Poongavanam V, Ermondi G. Steering New Drug Discovery Campaigns: Permeability, Solubility, and Physicochemical Properties in the bRo5 Chemical Space. ACS Med Chem Lett 2021;12:13-23. [PMID: 33488959 DOI: 10.1021/acsmedchemlett.0c00581] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 14.0] [Reference Citation Analysis]
116 O'Hagan S, Kell DB. Structural Similarities between Some Common Fluorophores Used in Biology, Marketed Drugs, Endogenous Metabolites, and Natural Products. Mar Drugs 2020;18:E582. [PMID: 33238416 DOI: 10.3390/md18110582] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
117 Rautio J, Meanwell NA, Di L, Hageman MJ. The expanding role of prodrugs in contemporary drug design and development. Nat Rev Drug Discov 2018;17:559-87. [DOI: 10.1038/nrd.2018.46] [Cited by in Crossref: 200] [Cited by in F6Publishing: 171] [Article Influence: 50.0] [Reference Citation Analysis]
118 Vásquez AF, Muñoz AR, Duitama J, González Barrios A. Non-Extensive Fragmentation of Natural Products and Pharmacophore-Based Virtual Screening as a Practical Approach to Identify Novel Promising Chemical Scaffolds. Front Chem 2021;9:700802. [PMID: 34422762 DOI: 10.3389/fchem.2021.700802] [Reference Citation Analysis]
119 Scott KA, Qureshi MH, Cox PB, Marshall CM, Bellaire BC, Wilcox M, Stuart BAR, Njardarson JT. A Structural Analysis of the FDA Green Book-Approved Veterinary Drugs and Roles in Human Medicine. J Med Chem 2020;63:15449-82. [PMID: 33125236 DOI: 10.1021/acs.jmedchem.0c01502] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
120 Hong RS, Miglani Bhardwaj R, Henry R, Mattei A, Diwan M, Thomas A, Danzer GD, Sheikh AY. Distinct Hybrid Hydrates of Paritaprevir: Combined Experimental and Computational Assessment of their Hydration–Dehydration Behavior and Implications for Regulatory Controls. Crystal Growth & Design 2022;22:726-37. [DOI: 10.1021/acs.cgd.1c01228] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
121 Maple HJ, Clayden N, Baron A, Stacey C, Felix R. Developing degraders: principles and perspectives on design and chemical space. Medchemcomm 2019;10:1755-64. [PMID: 31867093 DOI: 10.1039/c9md00272c] [Cited by in Crossref: 40] [Cited by in F6Publishing: 17] [Article Influence: 13.3] [Reference Citation Analysis]
122 Yokoo H, Shibata N, Endo A, Ito T, Yanase Y, Murakami Y, Fujii K, Hamamura K, Saeki Y, Naito M, Aritake K, Demizu Y. Discovery of a Highly Potent and Selective Degrader Targeting Hematopoietic Prostaglandin D Synthase via In Silico Design. J Med Chem 2021;64:15868-82. [PMID: 34652145 DOI: 10.1021/acs.jmedchem.1c01206] [Reference Citation Analysis]
123 Serafini M, Cargnin S, Massarotti A, Pirali T, Genazzani AA. Essential Medicinal Chemistry of Essential Medicines. J Med Chem 2020;63:10170-87. [PMID: 32352778 DOI: 10.1021/acs.jmedchem.0c00415] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
124 Polêto MD, Rusu VH, Grisci BI, Dorn M, Lins RD, Verli H. Aromatic Rings Commonly Used in Medicinal Chemistry: Force Fields Comparison and Interactions With Water Toward the Design of New Chemical Entities. Front Pharmacol 2018;9:395. [PMID: 29740321 DOI: 10.3389/fphar.2018.00395] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
125 Drummond ML, Williams CI. In Silico Modeling of PROTAC-Mediated Ternary Complexes: Validation and Application. J Chem Inf Model 2019;59:1634-44. [DOI: 10.1021/acs.jcim.8b00872] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 10.3] [Reference Citation Analysis]
126 Coleman N, Rodon J. Taking Aim at the Undruggable. Am Soc Clin Oncol Educ Book 2021;41:1-8. [PMID: 33989024 DOI: 10.1200/EDBK_325885] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
127 Koehl NJ, Henze LJ, Kuentz M, Holm R, Griffin BT. Supersaturated Lipid-Based Formulations to Enhance the Oral Bioavailability of Venetoclax. Pharmaceutics 2020;12:E564. [PMID: 32570753 DOI: 10.3390/pharmaceutics12060564] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
128 Barlow N, Chalmers DK, Williams-Noonan BJ, Thompson PE, Norton RS. Improving Membrane Permeation in the Beyond Rule-of-Five Space by Using Prodrugs to Mask Hydrogen Bond Donors. ACS Chem Biol 2020;15:2070-8. [PMID: 32628005 DOI: 10.1021/acschembio.0c00218] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
129 Tsantili-Kakoulidou A, Demopoulos VJ. Drug-like Properties and Fraction Lipophilicity Index as a combined metric. ADMET DMPK 2021;9:177-90. [PMID: 35300360 DOI: 10.5599/admet.1022] [Reference Citation Analysis]
130 Avdeef A, Kansy M. Predicting Solubility of Newly-Approved Drugs (2016–2020) with a Simple ABSOLV and GSE(Flexible-Acceptor) Consensus Model Outperforming Random Forest Regression. J Solution Chem. [DOI: 10.1007/s10953-022-01141-7] [Reference Citation Analysis]
131 Ruggeri M, Dombrowski AW, Djuric SW, Baxendale IR. Photochemical Flow Synthesis of 3‐Hydroxyazetidines. ChemPhotoChem 2019;3:1212-8. [DOI: 10.1002/cptc.201900188] [Cited by in Crossref: 9] [Article Influence: 3.0] [Reference Citation Analysis]
132 Kaddouri Y, Bouchal B, Abrigach F, El Kodadi M, Bellaoui M, Elkamhawy A, Touzani R, Abdellattif MH. New N-Alkylated Heterocyclic Compounds as Prospective NDM1 Inhibitors: Investigation of In Vitro and In Silico Properties. Pharmaceuticals 2022;15:803. [DOI: 10.3390/ph15070803] [Reference Citation Analysis]
133 Stone S, Newman DJ, Colletti SL, Tan DS. Cheminformatic analysis of natural product-based drugs and chemical probes. Nat Prod Rep 2021. [PMID: 34342327 DOI: 10.1039/d1np00039j] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
134 Cassidy K, Zhao H. Redefining the Scope of Targeted Protein Degradation: Translational Opportunities in Hijacking the Autophagy-Lysosome Pathway. Biochemistry 2021. [PMID: 34569233 DOI: 10.1021/acs.biochem.1c00330] [Reference Citation Analysis]
135 Tomaselli D, Mautone N, Mai A, Rotili D. Recent advances in epigenetic proteolysis targeting chimeras (Epi-PROTACs). European Journal of Medicinal Chemistry 2020;207:112750. [DOI: 10.1016/j.ejmech.2020.112750] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
136 Anane-Adjei AB, Jacobs E, Nash SC, Askin S, Soundararajan R, Kyobula M, Booth J, Campbell A. Amorphous Solid Dispersions: Utilization and Challenges in Preclinical Drug Development within AstraZeneca. Int J Pharm 2021;:121387. [PMID: 34933082 DOI: 10.1016/j.ijpharm.2021.121387] [Reference Citation Analysis]
137 Bhukya B, Fatima K, Nagar A, Lakshmi V, Dubey P, Kumar S, Kumar Y, Luqman S, Chanda D, Tandon S, Shanker K, Khan F, Negi AS. Brevifoliol ester induces apoptosis in prostate cancer cells by activation of caspase pathway. Chem Biol Drug Des 2020;95:150-61. [PMID: 31585016 DOI: 10.1111/cbdd.13631] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
138 Gonçalves LM, Trevisol ETV, de Azevedo Abrahim Vieira B, De Mesquita JF. Trehalose synthesis inhibitor: A molecular in silico drug design. J Cell Biochem 2020;121:1114-25. [PMID: 31478225 DOI: 10.1002/jcb.29347] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
139 Miethke M, Pieroni M, Weber T, Brönstrup M, Hammann P, Halby L, Arimondo PB, Glaser P, Aigle B, Bode HB, Moreira R, Li Y, Luzhetskyy A, Medema MH, Pernodet JL, Stadler M, Tormo JR, Genilloud O, Truman AW, Weissman KJ, Takano E, Sabatini S, Stegmann E, Brötz-Oesterhelt H, Wohlleben W, Seemann M, Empting M, Hirsch AKH, Loretz B, Lehr CM, Titz A, Herrmann J, Jaeger T, Alt S, Hesterkamp T, Winterhalter M, Schiefer A, Pfarr K, Hoerauf A, Graz H, Graz M, Lindvall M, Ramurthy S, Karlén A, van Dongen M, Petkovic H, Keller A, Peyrane F, Donadio S, Fraisse L, Piddock LJV, Gilbert IH, Moser HE, Müller R. Towards the sustainable discovery and development of new antibiotics. Nat Rev Chem 2021;:1-24. [PMID: 34426795 DOI: 10.1038/s41570-021-00313-1] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
140 Huang B, Zhang Y. Teaching an old dog new tricks: drug discovery by repositioning natural products and their derivatives. Drug Discov Today 2022:S1359-6446(22)00064-2. [PMID: 35182736 DOI: 10.1016/j.drudis.2022.02.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
141 Agarwal P, Ishida K, Reid DL, Gupta A. Clearance prediction for Amgen molecules against Extended Clearance Classification System (ECCS) and future directions. Drug Discov Today 2021;26:10-6. [PMID: 33075472 DOI: 10.1016/j.drudis.2020.10.008] [Reference Citation Analysis]